{"id":"NCT03855280","sponsor":"Medexus Pharma, Inc.","briefTitle":"Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B","officialTitle":"Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-16","primaryCompletion":"2022-07-04","completion":"2022-07-04","firstPosted":"2019-02-26","resultsPosted":"2024-05-16","lastUpdate":"2024-05-16"},"enrollment":21,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia B"],"interventions":[{"type":"DRUG","name":"APVO101","otherNames":["IB1001","Recombinant factor IX","IXINITY"]}],"arms":[{"label":"APVO101","type":"EXPERIMENTAL"}],"summary":"Phase 3/4, single arm, open-label study to evaluate PK, safety, and efficacy of APVO101 prophylaxis in severe or moderately severe hemophilia B subjects \\< 12 years of age.","primaryOutcome":{"measure":"Annualized Bleeding Rate (ABR)","timeFrame":"Exposure Day 1 up to 50 exposure days (approximately 6 months)","effectByArm":[{"arm":"APVO101 - Safety Population","deltaMin":2.93,"sd":4.59}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["Brazil","Georgia","Moldova","South Africa","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":21},"commonTop":["Bronchitis","Nasopharyngitis","Influenza","Respiratory tract infection","Respiratory tract infection viral"]}}